Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
[This article belongs to Volume - 26, Issue - 04]

Expression Patterns of VEGF in HER2 and TNBC: New Insights into Breast Cancer Biology

The objective of this study is to examine variations in the levels of Vascular Endothelial Growth Factor (VEGF) and Human Epidermal Growth Factor Receptor 2 (HER2) between Triple-Negative Breast Cancer (TNBC) and HER2-positive subtypes of breast cancer. The study employed a cross-sectional research design, which included a total of 38 breast cancer patients. Specifically, the sample consisted of 19 patients with triple-negative breast cancer (TNBC) and 19 patients with HER2-positive breast cancer. These patients were selected among those who received treatment at RSUD dr. Saiful Anwar Malang. The expression of VEGF was assessed via immunohistochemical staining and compared between the two groups. The results indicate a notable disparity in the expression of Vascular Endothelial Growth Factor (VEGF) between patients with Triple-Negative Breast Cancer (TNBC) and those with Human Epidermal Growth Factor Receptor 2 (HER2) type breast cancer. The mean VEGF expression in TNBC patients was 46.82, with a standard deviation of 13.22. The statistical analysis revealed a p-value of 0.004, signifying a substantial disparity in VEGF expression between the two groups. The data revealed a substantial elevation in VEGF expression among breast cancer patients with the HER2 subtype compared to those with the TNBC subtype. These findings offer further understanding of the biomolecular attributes of various types of breast tumors, along with possible clinical implications in the advancement of more precise detection and treatment approaches.